Leica Biosystems announces acquisition of Kreatech Diagnostics

NewsGuard 100/100 Score

Leica Biosystems announced that it has acquired Kreatech Diagnostics, a privately-held provider of DNA fluorescent in-situ hybridization (FISH) probes and target labeling reagents for microarrays.

"We are very pleased with the acquisition of Kreatech, its extensive portfolio and development expertise. This will allow Leica Biosystems to better serve our cytogenetics and anatomic pathology customers. It will also enable us to actively support the future development of personalized medicine by research and drug development companies" said Matthias G. Weber, MD, President of Leica Biosystems. "By standardizing and supporting the interpretation of results with our Aperio ePathologytm imaging solutions, we will provide our customers with the ability to effectively and efficiently manage ever more complex diagnostic requirements."

Kreatech will join Leica Biosystems' Advanced Staining Business Unit based in Newcastle-upon-Tyne, UK. The combined business will develop targeted biomarker menus for Leica's instrument platforms. Leica Biosystems provides the ThermoBrite®, and BOND™ systems that are widely used to label tissue specimens for diagnostic interpretation in cytogenetics and pathology laboratories globally.

"Leica Biosystems is a very natural fit to take Kreatech to the next stage" commented Kees Moonen, CEO of Kreatech Diagnostics. "Leica will bring global brand recognition, worldwide commercial reach, extensive cytogenetics and histology portfolios, and the automation of diagnostic tests on well-established systems. This will tremendously increase the number of customers that can benefit from Kreatech's superior solutions."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Evolving brain sizes from 1930 to 1970 could signal decreased dementia risk, researchers say